Browsing by Author "Lavrnic, Dragana (6602473221)"
Now showing 1 - 20 of 47
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Brain sonography insight into the midbrain in myotonic dystrophy type 2(2016) ;Rakocevic-stojanovic, Vidosava (6603893359) ;Peric, Stojan (35750481700) ;Savic-pavicevic, Dusanka (18435454500) ;Pesovic, Jovan (15725996300) ;Mesaros, Sarlota (7004307592) ;Lavrnic, Dragana (6602473221) ;Jovanovic, Zagorka (7006487114)Pavlovic, Aleksandra (7003808508)Introduction: The aim of this study was to analyze transcranial sonography (TCS) findings in genetically confirmed myotonic dystrophy type 2 (DM2) patients. Methods: Forty DM2 patients and 38 gender- and age-matched healthy controls (HCs) underwent TCS through the pre-auricular acoustic bone window. Results: Substantia nigra hyperechogenicity was found in 20% of DM2 patients compared with 3% of HCs. Brainstem raphe (BR) hypoechogenicity was more common in DM2 patients compared with HCs (56% vs. 10%, P<0.01), and it was more common in patients with fatigue and excessive daytime sleepiness (P<0.05). Diameter of the third ventricle was increased in DM2 patients compared with HCs (5.8±1.7 vs. 5.1±1.0mm, P<0.05). Conclusions: Finding BR hypoechogenicity might have clinical implication because of the potential response to serotonin-reuptake inhibitors. TCS revealed alterations in brain structures previously not seen in MRI studies. © 2016 Wiley Periodicals, Inc. - Some of the metrics are blocked by yourconsent settings
Publication Brain sonography insight into the midbrain in myotonic dystrophy type 2(2016) ;Rakocevic-stojanovic, Vidosava (6603893359) ;Peric, Stojan (35750481700) ;Savic-pavicevic, Dusanka (18435454500) ;Pesovic, Jovan (15725996300) ;Mesaros, Sarlota (7004307592) ;Lavrnic, Dragana (6602473221) ;Jovanovic, Zagorka (7006487114)Pavlovic, Aleksandra (7003808508)Introduction: The aim of this study was to analyze transcranial sonography (TCS) findings in genetically confirmed myotonic dystrophy type 2 (DM2) patients. Methods: Forty DM2 patients and 38 gender- and age-matched healthy controls (HCs) underwent TCS through the pre-auricular acoustic bone window. Results: Substantia nigra hyperechogenicity was found in 20% of DM2 patients compared with 3% of HCs. Brainstem raphe (BR) hypoechogenicity was more common in DM2 patients compared with HCs (56% vs. 10%, P<0.01), and it was more common in patients with fatigue and excessive daytime sleepiness (P<0.05). Diameter of the third ventricle was increased in DM2 patients compared with HCs (5.8±1.7 vs. 5.1±1.0mm, P<0.05). Conclusions: Finding BR hypoechogenicity might have clinical implication because of the potential response to serotonin-reuptake inhibitors. TCS revealed alterations in brain structures previously not seen in MRI studies. © 2016 Wiley Periodicals, Inc. - Some of the metrics are blocked by yourconsent settings
Publication Cardiologic predictors of sudden death in patients with myotonic dystrophy type 1(2013) ;Stojanovic, Vidosava Rakocevic (6603893359) ;Peric, Stojan (35750481700) ;Paunic, Teodora (55694005700) ;Pavlovic, Sanja (55391635400) ;Cvitan, Edita (36782138400) ;Basta, Ivana (8274374200) ;Peric, Marina (55243680800) ;Milicev, Milena (55243221400)Lavrnic, Dragana (6602473221)The aim of this study was to analyze survival, causes of death and cardiologic predictors of sudden death in a large cohort of patients with myotonic dystrophy type 1 (DM1). The study was comprised of 171 adult DM1 patients hospitalized at the Neurology Clinic in a 20-year period. Severe electrocardiographic (ECG) abnormality included at least one of the following: rhythm other than sinus, PR interval of ≥240 ms, QRS complex duration of 120 ms or more, and second-degree or third-degree atrioventricular (AV) block. Survival data were analyzed by the Kaplan-Meier test, log-rank test and Cox regression analysis. During the mean follow-up period of 9.4 ± 5.4 years, a pacemaker was implanted in 5.8% of DM1 patients and 14% of patients died. The mean age at death was 55.6 ± 12.5 years. The most common causes of death in our cohort were sudden death (41.7%) and respiratory failure (29.2%). The presence of palpitations (hazard ratio [HR] = 4.7, p < 0.05) and increased systolic blood pressure (HR = 9.8, p < 0.05) were significant predictors of sudden death. Among ECG parameters, severe ECG abnormality (HR = 4.7, p < 0.05), right bundle branch block (RBBB; HR = 3.9, p < 0.05) and bifascicular block (HR = 5.8, p < 0.05) were significant predictors of sudden death. © 2013 Elsevier Ltd. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Cardiologic predictors of sudden death in patients with myotonic dystrophy type 1(2013) ;Stojanovic, Vidosava Rakocevic (6603893359) ;Peric, Stojan (35750481700) ;Paunic, Teodora (55694005700) ;Pavlovic, Sanja (55391635400) ;Cvitan, Edita (36782138400) ;Basta, Ivana (8274374200) ;Peric, Marina (55243680800) ;Milicev, Milena (55243221400)Lavrnic, Dragana (6602473221)The aim of this study was to analyze survival, causes of death and cardiologic predictors of sudden death in a large cohort of patients with myotonic dystrophy type 1 (DM1). The study was comprised of 171 adult DM1 patients hospitalized at the Neurology Clinic in a 20-year period. Severe electrocardiographic (ECG) abnormality included at least one of the following: rhythm other than sinus, PR interval of ≥240 ms, QRS complex duration of 120 ms or more, and second-degree or third-degree atrioventricular (AV) block. Survival data were analyzed by the Kaplan-Meier test, log-rank test and Cox regression analysis. During the mean follow-up period of 9.4 ± 5.4 years, a pacemaker was implanted in 5.8% of DM1 patients and 14% of patients died. The mean age at death was 55.6 ± 12.5 years. The most common causes of death in our cohort were sudden death (41.7%) and respiratory failure (29.2%). The presence of palpitations (hazard ratio [HR] = 4.7, p < 0.05) and increased systolic blood pressure (HR = 9.8, p < 0.05) were significant predictors of sudden death. Among ECG parameters, severe ECG abnormality (HR = 4.7, p < 0.05), right bundle branch block (RBBB; HR = 3.9, p < 0.05) and bifascicular block (HR = 5.8, p < 0.05) were significant predictors of sudden death. © 2013 Elsevier Ltd. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Clinical and epidemiological features of Guillain-Barré syndrome in the Western Balkans(2014) ;Peric, Stojan (35750481700) ;Milosevic, Vuk (24480195100) ;Berisavac, Ivana (6507392420) ;Stojiljkovic, Olivera (56455361200) ;Beslac-Bumbasirevic, Ljiljana (6506489179) ;Marjanovic, Ivan (57201599576) ;Djuric, Vanja (35361619800) ;Djordjevic, Gordana (35763715800) ;Rajic, Sonja (56516616500) ;Cvijanovic, Milan (8208649800) ;Babic, Milica (56516407400) ;Dominovic, Aleksandra (56516864600) ;Vujovic, Balsa (57021631300) ;Cukic, Mirjana (55891936800) ;Petrovic, Milutin (36969833200) ;Toncev, Gordana (6506651230) ;Komatina, Nenad (56516845100) ;Martic, Vesna (6602650915)Lavrnic, Dragana (6602473221)The aim of this study was to define features of Guillain-Barré syndrome in a large cohort of patients from three Western Balkans countries. Data from adult Guillain-Barré syndrome (GBS) cases from 2009 to 2013 were retrospectively obtained from all tertiary health care centers. During the 5-year period, 327 new cases of GBS were identified with a male to female ratio of 1.7 : 1. The most common GBS variants were demyelinating (65%) and axonal (12%). At nadir 45% of patients were chair-bound, confined to bed, or required assisted ventilation, while 5% died. The crude incidence of GBS in Serbia and Montenegro was 0.93 per 100,000 population, and age-adjusted incidence according to the world standard population was 0.86 per 100,000. Incidence was particularly high in 50- to 80-year-old men. Statistically significant seasonal variations of GBS were not observed. This study of patients with GBS in the Western Balkans allows us to prepare the health system better and to improve the management of patients. This study also opens opportunities for international collaboration and for taking part in the multinational studies on GBS. © 2015 Peripheral Nerve Society. - Some of the metrics are blocked by yourconsent settings
Publication Clinical and epidemiological features of Guillain-Barré syndrome in the Western Balkans(2014) ;Peric, Stojan (35750481700) ;Milosevic, Vuk (24480195100) ;Berisavac, Ivana (6507392420) ;Stojiljkovic, Olivera (56455361200) ;Beslac-Bumbasirevic, Ljiljana (6506489179) ;Marjanovic, Ivan (57201599576) ;Djuric, Vanja (35361619800) ;Djordjevic, Gordana (35763715800) ;Rajic, Sonja (56516616500) ;Cvijanovic, Milan (8208649800) ;Babic, Milica (56516407400) ;Dominovic, Aleksandra (56516864600) ;Vujovic, Balsa (57021631300) ;Cukic, Mirjana (55891936800) ;Petrovic, Milutin (36969833200) ;Toncev, Gordana (6506651230) ;Komatina, Nenad (56516845100) ;Martic, Vesna (6602650915)Lavrnic, Dragana (6602473221)The aim of this study was to define features of Guillain-Barré syndrome in a large cohort of patients from three Western Balkans countries. Data from adult Guillain-Barré syndrome (GBS) cases from 2009 to 2013 were retrospectively obtained from all tertiary health care centers. During the 5-year period, 327 new cases of GBS were identified with a male to female ratio of 1.7 : 1. The most common GBS variants were demyelinating (65%) and axonal (12%). At nadir 45% of patients were chair-bound, confined to bed, or required assisted ventilation, while 5% died. The crude incidence of GBS in Serbia and Montenegro was 0.93 per 100,000 population, and age-adjusted incidence according to the world standard population was 0.86 per 100,000. Incidence was particularly high in 50- to 80-year-old men. Statistically significant seasonal variations of GBS were not observed. This study of patients with GBS in the Western Balkans allows us to prepare the health system better and to improve the management of patients. This study also opens opportunities for international collaboration and for taking part in the multinational studies on GBS. © 2015 Peripheral Nerve Society. - Some of the metrics are blocked by yourconsent settings
Publication COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis(2023) ;Peric, Stojan (35750481700) ;Rankovic, Milos (57942974000) ;Bozovic, Ivo (57194468421) ;Radosavljevic, Vanja (57942548800) ;Marjanovic, Ivan (57201599576) ;Basta, Ivana (8274374200)Lavrnic, Dragana (6602473221)Introduction: Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction which is typically presented with muscle weakness and excessive fatigability. Majority of MG patients require long-term immune suppression. Our aim was to analyze the frequency and severity of COVID-19 infection in MG patients, as well as the frequency of vaccinated MG patients against SARS-CoV-2. Methods: We included 125 MG patients from the central Belgrade municipalities—60% females, age at MG onset 50.1 ± 19.7 years, age at testing 61.7 ± 16.8 years, anti-acetylcholine receptor (anti-AChR) positive 78% and muscle specific tyrosine kinase (MuSK) positive 8.6%. Results: One-third of our MG patients had a COVID-19 infection and they were younger compared to those without verified COVID-19. Severe COVID-19 infection was registered in 28% of MG patients, mostly in elder subjects with comorbidities such as cardiac diseases and malignancies. MG worsening was noted in 21% of patients during/after COVID-19 and 42% had COVID-19 sequelae. Majority of MG patients were vaccinated against SARS-CoV-2 (almost 70%). Vaccination was more common among MG patients with diabetes and in those with a milder form of MG. The most common types of vaccines were Sinopharm (42%) and Pfizer-BioNTech (25.6%). Adverse events were observed in 36% of vaccinated patients, with flu-like symptoms (77%) and local reactions (13%) being the most common ones. MG worsening was noticed in 5 (5.8%) patients after vaccination. Conclusion: COVID-19 has placed a significant new burden for MG patients. Elder MG patients and patients with comorbidities are in higher risk of having adverse outcome following SARS-CoV-2 infection. Percentage of vaccinated MG patients was higher than in general Serbian population. © 2022, The Author(s) under exclusive licence to Belgian Neurological Society. - Some of the metrics are blocked by yourconsent settings
Publication Diabetes mellitus may affect short-term outcome of Guillain-Barré syndrome(2017) ;Peric, Stojan (35750481700) ;Bozovic, Ivo (57194468421) ;Bjelica, Bogdan (57194461405) ;Berisavac, Ivana (6507392420) ;Stojiljkovic, Olivera (56455361200) ;Basta, Ivana (8274374200) ;Beslac-Bumbasirevic, Ljiljana (6506489179) ;Rakocevic-Stojanovic, Vidosava (6603893359) ;Lavrnic, Dragana (6602473221)Stevic, Zorica (57204495472)We sought to determine influence of diabetes mellitus on Guillain-Barré syndrome (GBS) course and short-term prognosis. Among the 257 GBS patients included in this retrospective study, diabetes mellitus was present in 17%. The degree of disability at admission and on discharge was assessed according to the GBS Disability Scale (mild disability = 0–3, severe disability = 4–6). Even after correction for age, diabetes mellitus was significantly associated with more severe disability at nadir (odds ratio, OR = 3.4, p < 0.05) and on discharge (OR = 2.0, p < 0.05). Linear regression analysis with multiple factors included showed that age and presence of diabetes were significant predictors of severe disability at nadir (adjusted R2 = 0.21, p < 0.05), and on discharge (adjusted R2 = 0.19, p < 0.05). The presence of diabetes mellitus affects short-term prognosis of GBS, independent of age. © 2017 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Diabetes mellitus may affect short-term outcome of Guillain-Barré syndrome(2017) ;Peric, Stojan (35750481700) ;Bozovic, Ivo (57194468421) ;Bjelica, Bogdan (57194461405) ;Berisavac, Ivana (6507392420) ;Stojiljkovic, Olivera (56455361200) ;Basta, Ivana (8274374200) ;Beslac-Bumbasirevic, Ljiljana (6506489179) ;Rakocevic-Stojanovic, Vidosava (6603893359) ;Lavrnic, Dragana (6602473221)Stevic, Zorica (57204495472)We sought to determine influence of diabetes mellitus on Guillain-Barré syndrome (GBS) course and short-term prognosis. Among the 257 GBS patients included in this retrospective study, diabetes mellitus was present in 17%. The degree of disability at admission and on discharge was assessed according to the GBS Disability Scale (mild disability = 0–3, severe disability = 4–6). Even after correction for age, diabetes mellitus was significantly associated with more severe disability at nadir (odds ratio, OR = 3.4, p < 0.05) and on discharge (OR = 2.0, p < 0.05). Linear regression analysis with multiple factors included showed that age and presence of diabetes were significant predictors of severe disability at nadir (adjusted R2 = 0.21, p < 0.05), and on discharge (adjusted R2 = 0.19, p < 0.05). The presence of diabetes mellitus affects short-term prognosis of GBS, independent of age. © 2017 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Disability and quality of life in Guillain-Barré syndrome – Longitudinal study(2020) ;Berisavac, Ivana (6507392420) ;Arsenijevic, Mirjana (57357620400) ;Bozovic, Ivo (57194468421) ;Mladenovic, Branka (57216509488) ;Kacar, Aleksandra (6602386522) ;Stojiljkovic Tamas, Olivera (57202112475) ;Petrovic, Milutin (36969833200) ;Stojanovic, Miroslav (55442973200) ;Vujovic, Balsa (57021631300) ;Martic, Vesna (6602650915) ;Jovanovic, Dejana (55419203900) ;Lavrnic, Dragana (6602473221) ;Basta, Ivana (8274374200)Peric, Stojan (35750481700)Longitudinal health-related quality of life (QoL) data in Guillain-Barré (GBS) patients are still scarce. We, therefore, investigated health- related QoL in GBS patients from Serbia and surrounding countries during a six-month follow-up period, and analyzed its association with patients' disability. Our study comprised 74 adult patients diagnosed with GBS from May 2017 until May 2018 in seven tertiary healthcare centers. Health-related QoL was investigated using the SF-36 questionnaire, and compared with functional disability assessed by the GBS disability scale (GDS). Tests were performed at day 14, day 28, month 3 and month 6 from disease onset. GDS and SF-36 scores improved over time (p < 0.01). GDS scores were different at all four time points, while SF-36 did not differ between day 14 and day 28. Pooled SF-36 scores (especially physical ones) correlated with pooled GDS scores, except for Bodily Pain and Role Emotional scores. We found that GDS score at day 14 was an independent predictor of GDS score at month 6 (β = +0.52, p < 0.01), while SF-36 score at day 14 was an independent predictor of SF-36 score at month 6 (β = +0.51, p < 0.01). Neurologists should look not only on disability but also on QoL in GBS patients, since these two measures provide us with important complementary items of information. © 2020 Elsevier Ltd - Some of the metrics are blocked by yourconsent settings
Publication Disability and quality of life in Guillain-Barré syndrome – Longitudinal study(2020) ;Berisavac, Ivana (6507392420) ;Arsenijevic, Mirjana (57357620400) ;Bozovic, Ivo (57194468421) ;Mladenovic, Branka (57216509488) ;Kacar, Aleksandra (6602386522) ;Stojiljkovic Tamas, Olivera (57202112475) ;Petrovic, Milutin (36969833200) ;Stojanovic, Miroslav (55442973200) ;Vujovic, Balsa (57021631300) ;Martic, Vesna (6602650915) ;Jovanovic, Dejana (55419203900) ;Lavrnic, Dragana (6602473221) ;Basta, Ivana (8274374200)Peric, Stojan (35750481700)Longitudinal health-related quality of life (QoL) data in Guillain-Barré (GBS) patients are still scarce. We, therefore, investigated health- related QoL in GBS patients from Serbia and surrounding countries during a six-month follow-up period, and analyzed its association with patients' disability. Our study comprised 74 adult patients diagnosed with GBS from May 2017 until May 2018 in seven tertiary healthcare centers. Health-related QoL was investigated using the SF-36 questionnaire, and compared with functional disability assessed by the GBS disability scale (GDS). Tests were performed at day 14, day 28, month 3 and month 6 from disease onset. GDS and SF-36 scores improved over time (p < 0.01). GDS scores were different at all four time points, while SF-36 did not differ between day 14 and day 28. Pooled SF-36 scores (especially physical ones) correlated with pooled GDS scores, except for Bodily Pain and Role Emotional scores. We found that GDS score at day 14 was an independent predictor of GDS score at month 6 (β = +0.52, p < 0.01), while SF-36 score at day 14 was an independent predictor of SF-36 score at month 6 (β = +0.51, p < 0.01). Neurologists should look not only on disability but also on QoL in GBS patients, since these two measures provide us with important complementary items of information. © 2020 Elsevier Ltd - Some of the metrics are blocked by yourconsent settings
Publication Evaluation of the adequacy of requests for electrodiagnostic examination in a tertiary referral center(2016) ;Nikolic, Ana (19933823000) ;Stevic, Zorica (57204495472) ;Peric, Stojan (35750481700) ;Stojanovic, Vidosava Rakocevic (6603893359)Lavrnic, Dragana (6602473221)Objective Diagnostic procedures are often overused in the attempt to substitute for the good clinical examination. The aim of this study was to evaluate the type and the accuracy of the referral diagnosis to our EMG lab, as well as the impact of electrodiagnostic (EDX) examination on the diagnosis of our patients. Methods In this prospective study all patients examined in the six months period in a single tertiary referral EMG lab were analyzed. All patients were tested in a uniform fashion and by the same neurologist, according to the referral diagnosis. Results EDX examination was performed in 570 patients. Most of the patients (43.9%) were referred with the diagnosis of polyneuropathy, lumbosacral (23.7%) or cervical (11.2%) radiculopathy and myasthenia gravis (11.6%). The outcome after EDX examination was: diagnosis confirmation in 49.6% of patients, new clinically relevant diagnosis in 16%, incidental diagnosis in 4% and normal EDX examination in 36.1% of patients. EDX examination confirmed referral diagnosis more often in patients referred by neuromuscular neurologists, while normal EDX finding was reported more often in patients referred by other neurologists. Conclusion This study has confirmed the inappropriateness of a large number of referrals to EDX testing, especially made by the non-neuromuscular neurologists. © 2016 Elsevier B.V. - Some of the metrics are blocked by yourconsent settings
Publication Frequency and features of the central poststroke pain(2018) ;Vukojevic, Zoran (26025746700) ;Dominovic Kovacevic, Aleksandra (37028225600) ;Peric, Stojan (35750481700) ;Grgic, Sanja (56698137700) ;Bjelica, Bogdan (57194461405) ;Basta, Ivana (8274374200)Lavrnic, Dragana (6602473221)Background: Central poststroke pain (CPSP) is often unrecognized in clinical practice, it may aggravate the rehabilitation process and reduce quality of life. Aim: To determine the frequency and features of CPSP, as well as to make possible associations of CPSP with sociodemographic and clinical features of subjects with stroke. Method: In a two-year period 602 patients with previous stroke were consecutively tested. We used three questionnaires for the diagnosis of neuropathic pain (Pain Detect Questionnaire - PD-Q, The Leeds Assessment of Neuropathic Symptoms and Signs - LANSS and Douleur neuropatathique en 4 questions - DN4). Results: CPSP was present in 12% of our patients with stroke, and usually occurred in the first several months after stroke. It was associated with cortical and thalamic localization of stroke, higher level of functional disability, as well as with younger age. The most important features that distinguish CPSP from other types of pain were presence of allodynia and pricking hypoesthesia, while other neuropathic sensations were common in stroke subjects both with and without CPSP. Conclusion: Younger subjects with cortical/thalamic stroke and higher level of disability should be thoroughly examined for the presence of neuropatic pain, since this may highly influence therapeutic strategy and quality of life in these subjects. © 2018 Elsevier B.V. - Some of the metrics are blocked by yourconsent settings
Publication Frequency and features of the central poststroke pain(2018) ;Vukojevic, Zoran (26025746700) ;Dominovic Kovacevic, Aleksandra (37028225600) ;Peric, Stojan (35750481700) ;Grgic, Sanja (56698137700) ;Bjelica, Bogdan (57194461405) ;Basta, Ivana (8274374200)Lavrnic, Dragana (6602473221)Background: Central poststroke pain (CPSP) is often unrecognized in clinical practice, it may aggravate the rehabilitation process and reduce quality of life. Aim: To determine the frequency and features of CPSP, as well as to make possible associations of CPSP with sociodemographic and clinical features of subjects with stroke. Method: In a two-year period 602 patients with previous stroke were consecutively tested. We used three questionnaires for the diagnosis of neuropathic pain (Pain Detect Questionnaire - PD-Q, The Leeds Assessment of Neuropathic Symptoms and Signs - LANSS and Douleur neuropatathique en 4 questions - DN4). Results: CPSP was present in 12% of our patients with stroke, and usually occurred in the first several months after stroke. It was associated with cortical and thalamic localization of stroke, higher level of functional disability, as well as with younger age. The most important features that distinguish CPSP from other types of pain were presence of allodynia and pricking hypoesthesia, while other neuropathic sensations were common in stroke subjects both with and without CPSP. Conclusion: Younger subjects with cortical/thalamic stroke and higher level of disability should be thoroughly examined for the presence of neuropatic pain, since this may highly influence therapeutic strategy and quality of life in these subjects. © 2018 Elsevier B.V. - Some of the metrics are blocked by yourconsent settings
Publication Frontostriatal dysexecutive syndrome: A core cognitive feature of myotonic dystrophy type 2(2015) ;Peric, Stojan (35750481700) ;Mandic-Stojmenovic, Gorana (55780903300) ;Stefanova, Elka (7004567022) ;Savic-Pavicevic, Dusanka (18435454500) ;Pesovic, Jovan (15725996300) ;Ilic, Vera (56396353100) ;Dobricic, Valerija (22952783800) ;Basta, Ivana (8274374200) ;Lavrnic, Dragana (6602473221)Rakocevic-Stojanovic, Vidosava (6603893359)The aim of this study was to assess cognitive status in a large group of patients with myotonic dystrophy type 2 (DM2) compared to type 1 (DM1) subjects matched for gender and age, using a comprehensive battery of neuropsychological tests. Thirty-four genetically confirmed adult DM2 patients were recruited and matched for gender and age with 34 adult-onset DM1 subjects. All patients underwent detailed classic pen and pencil neuropsychological investigation and also computerized automated battery—CANTAB. More than half of DM2 patients had abnormal results on executive tests [Intra/Extradimensional Set Shift (IED), Stockings of Cambridge (SOC)] and verbal episodic memory (Ray Auditory Verbal Learning Test). Regarding DM1, abnormal results in more than 50 % of subjects were achieved in even ten tests, including visuospatial, language, executive, cognitive screening and visual memory tests. Direct comparison between patient groups showed that lower percentage of DM2 patients had abnormal results on following tests: Addenbrooke’s Cognitive Examination—Revised, Raven Standard Progressive Matrices, Block Design, copy and recall of Rey-Osterieth Complex Figure, number of categories and perseverative responses on Wisconsin Card Sorting Test and Boston Naming Test (p\0.01), as well as Trail Making Test—B and Spatial Span (p\0.05). Our results showed significant dysexecutive syndrome and certain impairment of episodic verbal memory in DM2 patients that are reflective of frontal (especially frontostriatal) and temporal lobe dysfunction. On the other hand, dysexecutive and visuospatial/ visuoconstructional deficits predominate in DM1 which correspond to the frontal, parietal (and occipital) lobe dysfunction. © Springer-Verlag Berlin Heidelberg 2014. - Some of the metrics are blocked by yourconsent settings
Publication Frontostriatal dysexecutive syndrome: A core cognitive feature of myotonic dystrophy type 2(2015) ;Peric, Stojan (35750481700) ;Mandic-Stojmenovic, Gorana (55780903300) ;Stefanova, Elka (7004567022) ;Savic-Pavicevic, Dusanka (18435454500) ;Pesovic, Jovan (15725996300) ;Ilic, Vera (56396353100) ;Dobricic, Valerija (22952783800) ;Basta, Ivana (8274374200) ;Lavrnic, Dragana (6602473221)Rakocevic-Stojanovic, Vidosava (6603893359)The aim of this study was to assess cognitive status in a large group of patients with myotonic dystrophy type 2 (DM2) compared to type 1 (DM1) subjects matched for gender and age, using a comprehensive battery of neuropsychological tests. Thirty-four genetically confirmed adult DM2 patients were recruited and matched for gender and age with 34 adult-onset DM1 subjects. All patients underwent detailed classic pen and pencil neuropsychological investigation and also computerized automated battery—CANTAB. More than half of DM2 patients had abnormal results on executive tests [Intra/Extradimensional Set Shift (IED), Stockings of Cambridge (SOC)] and verbal episodic memory (Ray Auditory Verbal Learning Test). Regarding DM1, abnormal results in more than 50 % of subjects were achieved in even ten tests, including visuospatial, language, executive, cognitive screening and visual memory tests. Direct comparison between patient groups showed that lower percentage of DM2 patients had abnormal results on following tests: Addenbrooke’s Cognitive Examination—Revised, Raven Standard Progressive Matrices, Block Design, copy and recall of Rey-Osterieth Complex Figure, number of categories and perseverative responses on Wisconsin Card Sorting Test and Boston Naming Test (p\0.01), as well as Trail Making Test—B and Spatial Span (p\0.05). Our results showed significant dysexecutive syndrome and certain impairment of episodic verbal memory in DM2 patients that are reflective of frontal (especially frontostriatal) and temporal lobe dysfunction. On the other hand, dysexecutive and visuospatial/ visuoconstructional deficits predominate in DM1 which correspond to the frontal, parietal (and occipital) lobe dysfunction. © Springer-Verlag Berlin Heidelberg 2014. - Some of the metrics are blocked by yourconsent settings
Publication Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: Their role in malignancy development and response to therapy(2014) ;Milosevic, Zorica (57209726720) ;Tanic, Nikola (7801574805) ;Bankovic, Jasna (24278374400) ;Stankovic, Tijana (55321765700) ;Buta, Marko (16202214500) ;Lavrnic, Dragana (6602473221) ;Milovanovic, Zorka (25228841900) ;Pupic, Gordana (6507142544) ;Stojkovic, Sonja (55915641500) ;Milinkovic, Vedrana (35810904900) ;Ito, Yasuhiro (35427371100)Dzodic, Radan (6602410321)Multiple cancers represent 2.42% of all human cancers and are mainly double or triple cancers. Many possible causes of multiple malignancies have been reported such as genetic alterations, exposure to anti-cancer chemotherapy, radiotherapy, immunosuppressive therapy and reduced immunologic response. We report a female patient with multiple sclerosis and quadruple cancers of different embryological origin. Patient was diagnosed with stage III (T3, N1a, MO) medullary thyroid carcinoma (MTC), multicentric micropapillary thyroid carcinoma, scapular and lumbar melanomas (Clark II, Breslow II), and lobular invasive breast carcinoma (T1a, NO, MO). All tumors present in our patient except micropapillary thyroid carcinomas were investigated for gene alterations known to have a key role in cancer promotion and progression. Tumor samples were screened for the p16 alterations (loss of heterozygosity and homozygous deletions), loss of heterozygosity of PTEN, p53 alterations (mutational status and loss of heterozygosity) and mutational status of RET, HRAS and KRAS. Each type of tumor investigated had specific pattern of analyzed genetic alterations. The most prominent genetic changes were mutual alterations in PTEN and p53 tumor suppressors present in breast cancer and two melanomas. These co-alterations could be crucial for promoting development of multiple malignancies. Moreover the insertion in 4th codon of HRAS gene was common for all tumor types investigated. It represents frameshift mutation introducing stop codon at position 5 which prevents synthesis of a full-length protein. Since the inactivated RAS enhances sensitivity to tamoxifen and radiotherapy this genetic alteration could be considered as a good prognostic factor for this patient. - Some of the metrics are blocked by yourconsent settings
Publication Guillain-Barré syndrome in the elderly(2016) ;Peric, Stojan (35750481700) ;Berisavac, Ivana (6507392420) ;Stojiljkovic Tamas, Olivera (57202112475) ;Rajic, Sonja (56516616500) ;Babic, Milica (56516407400) ;Cvijanovic, Milan (8208649800) ;Dominovic-Kovacevic, Aleksandra (37028225600) ;Basta, Ivana (8274374200) ;Beslac-Bumbasirevic, Ljiljana (6506489179)Lavrnic, Dragana (6602473221)The aim of the study was to analyze specific features of Guillain-Barré syndrome (GBS) in old people. The study included 403 GBS patients (62% young [<60 years], 35% young-old [60–80 years], and 3% old-old [>80 years]). Diagnosis of GBS was made according to the National Institute of Neurological Disorders and Stroke (NINDS criteria). Severe disability (GBS disability score of >3) at nadir was more common in old compared with young patients (p = 0.0001) as was mortality (9% vs. 2%, respectively). Acute motor and sensory axonal neuropathy and hyponatremia were more common in old compared with young patients (12% vs. 6% and 27% vs. 18%, respectively, p = 0.04). A positive history for malignancy was more than three times more common in old than young patients (11% vs. 3%, respectively, p = 0.01). Disability on nadir was similar in young-old and old-old subjects with disability on discharge being more severe in old-old (p = 0.04) suggesting slower recovery in this subgroup. Bulbar symptoms were more common in old-old compared with young-old (50% vs. 19%, respectively, p = 0.01). Comorbidities were present in virtually all old-old patients compared with 66% of young-old patients (p = 0.04). In conclusion, Elderly patients, and especially old-old patients, with GBS have more severe disease with slower recovery than do younger patients. © 2016 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Guillain-Barré syndrome in the elderly(2016) ;Peric, Stojan (35750481700) ;Berisavac, Ivana (6507392420) ;Stojiljkovic Tamas, Olivera (57202112475) ;Rajic, Sonja (56516616500) ;Babic, Milica (56516407400) ;Cvijanovic, Milan (8208649800) ;Dominovic-Kovacevic, Aleksandra (37028225600) ;Basta, Ivana (8274374200) ;Beslac-Bumbasirevic, Ljiljana (6506489179)Lavrnic, Dragana (6602473221)The aim of the study was to analyze specific features of Guillain-Barré syndrome (GBS) in old people. The study included 403 GBS patients (62% young [<60 years], 35% young-old [60–80 years], and 3% old-old [>80 years]). Diagnosis of GBS was made according to the National Institute of Neurological Disorders and Stroke (NINDS criteria). Severe disability (GBS disability score of >3) at nadir was more common in old compared with young patients (p = 0.0001) as was mortality (9% vs. 2%, respectively). Acute motor and sensory axonal neuropathy and hyponatremia were more common in old compared with young patients (12% vs. 6% and 27% vs. 18%, respectively, p = 0.04). A positive history for malignancy was more than three times more common in old than young patients (11% vs. 3%, respectively, p = 0.01). Disability on nadir was similar in young-old and old-old subjects with disability on discharge being more severe in old-old (p = 0.04) suggesting slower recovery in this subgroup. Bulbar symptoms were more common in old-old compared with young-old (50% vs. 19%, respectively, p = 0.01). Comorbidities were present in virtually all old-old patients compared with 66% of young-old patients (p = 0.04). In conclusion, Elderly patients, and especially old-old patients, with GBS have more severe disease with slower recovery than do younger patients. © 2016 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Long-term outcome in patients with myasthenia gravis: one decade longitudinal study(2022) ;Bozovic, Ivo (57194468421) ;Ilic Zivojinovic, Jelena (57205711393) ;Peric, Stojan (35750481700) ;Kostic, Marko (57194713012) ;Ivanovic, Vukan (57211858030) ;Lavrnic, Dragana (6602473221)Basta, Ivana (8274374200)Introduction: Even treated, myasthenia gravis (MG) continues to represent a significant burden and might continuously affect patients’ quality of life (QoL). The aim of our longitudinal study was to analyze QoL in a large cohort of MG patients after a 10-year follow-up period. Methods: This study comprised 78 MG patients (60% females, 50 ± 16 years old at baseline, 70% AchR positive) who were retested after 10 years. Disease severity was evaluated by MGFA classification. QoL was assessed using SF-36 questionnaire and Myasthenia Gravis-specific Questionnaire (MGQ). Hamilton rating scales for depression and anxiety (HDRS and HARS), Multidimensional Scale of Perceived Social Support (MSPSS) and Acceptance of Illness Scale (AIS) were also used. Results: Similar percentage of patients was in remission at both time points (42% and 45%). However, at baseline all patients were treated, while 32% were treatment-free at follow-up. SF-36, MGQ, MSPSS and AIS scores were similar at baseline and retest. Mean HDRS and HARS scores worsened during time (p < 0.05), although percentage of patients with depression and anxiety did not change significantly. Significant predictors of worse SF-36 score at retest were depression (β = − 0.45, p < 0.01), poor disease acceptance (β = − 0.44, p < 0.01) and older age (β = − 0.30, p < 0.01). Significant predictors of worse MGQ score at retest were poor disease acceptance (β = − 0.40, p < 0.01), retirement (β = − 0.36, p < 0.01), lower education (β = 0.25, p < 0.01), and depression (β = − 0.18, p < 0.05). Conclusions: Although after 10 years, a significant number of MG patients were in remission, their QoL was still reduced. Neurologists should be aware that patients’ perception of poor QoL may persist even if MG is well treated from a physician’s perspective. © 2021, Springer-Verlag GmbH Germany, part of Springer Nature.
- «
- 1 (current)
- 2
- 3
- »